Evidence map›Paper›PMID 39276378›Full record

ArticleAging2024

Intraovarian PRP injection improves oocyte quality and early embryo development in mouse models of chemotherapy-induced diminished ovarian reserve.

Mauro Cozzolino, Yagmur Ergun, Denis A Seli, Sonia Herraiz

Abstract read
In one paragraph

Article in Aging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Mauro CozzolinoIVIRMA Global Research Alliance, IVI Foundation-IIS la Fe, Valencia 46026, Spain.
Yagmur ErgunDepartment of Obstetrics, Gynecology and Reproductive Sciences, New Heaven, CT 06510, USA.
Denis A SeliIVIRMA Global Research Alliance, IVI Foundation-IIS la Fe, Valencia 46026, Spain.
Sonia HerraizIVIRMA Global Research Alliance, IVI Foundation-IIS la Fe, Valencia 46026, Spain.

Funding

6500 QTrap Mass Spectrometer for Yale UniversityS10OD018034 · OD · YALE UNIVERSITY · PI MANE, SHRIKANT M · 2014 to 2014
$514k
An Ultra-Performance Liquid Chromatography System to Support Metabolomics at Yale UniversityS10OD019967 · OD · YALE UNIVERSITY · PI LAM, TUKIET T · 2015 to 2015
$135k
NIH HHS S10 OD018034NIH HHS S10 OD019967
6 · The paper itself

Abstract

Intraovarian injection of platelet-rich plasma (PRP) has been recently proposed, with encouraging results to provide an alternative option to patients diagnosed with POR or POI. However, the broad spectrum of PRP effects on the reproductive function and the mechanisms of action in follicular activation, response to stimulation, and embryo quality have not yet been studied. In this study, we first induced poor ovarian reserve (POR) and premature ovarian insufficiency (POI) ovarian phenotypes in CD1 mice undergoing PRP or sham intraovarian injection. PRP administration reduced those alterations induced by chemotherapy in ovarian stroma and follicle morphology in both the POR and POI conditions. After ovarian stimulation, we found that PRP did not modify the MII-oocyte yield. Nevertheless, the amount of obtained 2-cell embryos and fertilization rate were increased, being especially relevant for the POI model. Further

Indexed as

Embryonic DevelopmentOocytesOvarian ReservePlatelet-Rich PlasmaPrimary Ovarian InsufficiencyAnimalsAntineoplastic AgentsDisease Models, AnimalFemaleMiceMice, Inbred C57BLAntineoplastic Agentsplatelet-rich plasma ovarian injectionpoor ovarian reservepremature ovarian insufficiency

Identifiers

PMID39276378
PMCPMC11424580

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.